表紙
市場調查報告書
商品編碼
953238

全球生物製藥市場:2020-2024

Curative Oncology and Rare Disease Therapies Transforming the Global Biologics Market, 2020-2024

出版日期: | 出版商: Frost & Sullivan | 英文 118 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球生物製藥(biopharmaceutical)市場包括四個主要領域:抗體療法,重組蛋白,疫苗和再生醫學。

此報告調查和分析了全球生物製藥(生物製藥)市場,並提供了有關市場概況,市場動態,收益預測,細分分析,主要公司,增長機會等的系統信息。

目錄

行政儀表板

市場概況:生物產品

  • 範圍
  • 市場細分
  • 主要產品類別的描述
  • 生物製劑的特徵
  • 生物製品的生命週期
  • 市場促進因素/抑制因素

市場動態

  • 領先的生物製劑公司
  • 生物製品的研發費用
  • 生物製品批准的監管框架
  • 按地區劃分的藥品批准趨勢
  • 再生醫學市場進入的主要問題

分析COVID-19對生物製劑市場的影響

  • COVID-19大流行對生物製劑市場的高水平影響
  • 關於生物製品的生產和供應線的問題
  • 靶向COVID-19(SARS-COV-2)的生物製藥管道
  • 收入預測:調查COVID-19影響的方法
  • 大流行後生物製劑市場未來成功所必不可少的增長機會
  • 推薦的行為(C2A)
  • 基於COVID-19的企業戰略要求

收入預測:整體生物製劑市場

  • 調查方法
  • 市場工程測量
  • 收入預測:COVID-19之前和之後的影響
  • 產品細分
  • 整體生物市場:十大產品
  • 故障:按治療領域
  • 力學變化
  • 按產品類型預測的收入比率

抗體治療領域分析

  • 抗體療法:十大產品概述
  • 市場工程測量
  • 收入預測
  • 收入預測討論
  • 預計主要產品上市
  • 力學變化
  • 抗體治療平台的技術趨勢

重組蛋白片段分析

  • 重組蛋白:十大產品概述
  • 市場工程測量
  • 收入預測
  • 收入預測討論
  • 預計主要產品上市
  • 力學變化

疫苗分類分析

  • 疫苗:十大產品概述
  • 市場工程測量
  • 收入預測
  • 收入預測討論
  • 預計主要產品上市
  • 力學變化

細胞療法/基因療法細分分析

  • 細胞療法/基因療法:十大產品概述
  • 市場工程測量
  • 收入預測
  • 收入預測討論
  • 細胞治療平台的技術趨勢
  • 預計主要產品上市
  • 力學變化
  • RNA/病毒載體平台的技術趨勢

關鍵公司:管道分析

  • Roche AG
  • AMGEN
  • Sanofi
  • AbbVie
  • Novo Nordisk
  • Merck
  • Pfizer
  • Johnson & Johnson
  • Eli Lilly
  • GlaxoSmithKline

    增長機會

    • 主要增長機會
    • 增長機會1
    • 增長機會2
    • 增長機會3等

    摘要

    附錄

  • 目錄
    Product Code: MEAA-52

    Strategic Collaborations with Specialty Bio-CDMOs will Continue to Drive Growth Opportunities in Antibody-drug Conjugates and Gene Therapies

    With this research service, Frost & Sullivan's ‘Transformational Health team’ provides critical insights into the global biologics industry highlighting the growth opportunities, market revenue segmentation, and technology trends influencing its growth. The global biologics market covered in this study includes 4 major segments - antibody therapies, recombinant proteins, vaccines, and regenerative medicine. The forecast for the global biologics market till 2024 reveals interesting trend and paradigm shifts that are set to take place in the industry. Importantly, the study also identifies actionable growth opportunities for industry participants to profit upon.

    This research service identifies the largest revenue-generating segments and key therapeutic areas for the global biologics industry. Accelerated regulatory approvals for biologic products and the emergence of next-generation technologies are highlighted, in addition to their influence on market trends during the forecast period. The study highlights the dynamics of the biologics industry and the sub-segments of the biologics market. Growth opportunities in antibody-drug conjugate (ADC), RNA therapy, and gene therapy platforms are also explored. Further, the study discusses the impact (such as the accelerated development of vaccines) of the COVID-19 pandemic on the biologics industry and the market. Current challenges facing the biologics industry such as the sluggish growth rate of vaccines, and recombinant proteins are discussed. Most importantly, this research service discusses possible future market trends such as the accelerated development of mRNA-based vaccines and the increasing importance of specialty bio-CDMOs for the development and commercialization of regenerative medicine. Based on the market trends and revenue forecasts, Frost & Sullivan's group of analysts highlight key growth opportunities in ADC, RNA, and gene therapy platforms through successful drug launches such as Belantamab Malfodotin, Inclisiran, and Zolgensma.

    Research Highlights:

    Highlights of the report include:

    • Market revenue forecast for the global biologics market till 2024
    • Segment-wise revenue forecast of the top market players and key therapeutic areas
    • Top 3 predictions for the global biologics market
    • Technology trends influencing the future outlook of the biologics market
    • Growth opportunities in the global biologics market
    • Strategic recommendations for the biologics market
    • COVID-19 impact analysis on the biologics market

    Key Issues Addressed:

    • What will be the revenue and growth rate for the global biologics market from 2020 to 2024?
    • What will be the major segments influencing this revenue and growth rate?
    • What are the key technologies and trends to watch for during the forecast period?
    • What are the major growth opportunities in the biologics industry?
    • What are the top predictions for the biologics market?

    Table of Contents

    Executive Dashboard

    • Purpose of this Study
    • Methodology
    • 5-step Process to Transformational Growth
    • Key Findings
    • Key Questions this Study will Answer
    • Market Engineering Measurements
    • Transformation in the Industry Ecosystem
    • Macro Trends-Biologics Discovery, Development and Manufacturing
    • Technology Trends-Biologics Discovery, Development and Manufacturing
    • 5 Big Themes for the Global Biologics Market
    • Strategic Imperatives for the Biologics Market

    Market Overview-Biologics

    • Scope
    • Market Segmentation
    • Description of Main Product Categories
    • Characteristics of Biologics
    • Lifecycle of Biologics Products
    • Market Drivers and Restraints

    Market Dynamics

    • Key Biologics Companies
    • Biologics R&D Expenditure
    • Regulatory Framework for Biologics Approval
    • Region-wise Regulatory Drug Approval Trends
    • Key Issues in Market Entry for Regenerative Medicine

    COVID-19 Impact Analysis on the Biologics Market

    • Top-level Impact of COVID-19 Pandemic on the Biologics Market
    • Biologics Manufacturing and Supply Line Challenges
    • Biologics Pipeline Targeting COVID-19 (SARS-COV-2)
    • Revenue Forecast-COVID-19 Impact Methodology
    • Growth Opportunities Critical for Future Success in a Post-pandemic Biologics Market
    • Companies to Action
    • Strategic Imperatives for Companies in Light of COVID-19

    Revenue Forecast-Total Biologics Market

    • Methodology
    • Market Engineering Measurements
    • Revenue Forecast-Pre-COVID-19 vs. Post-COVID-19 Impact
    • Product Segmentation
    • Total Biologics Market-Top 10 Products
    • Breakdown by Therapeutic Area
    • Changing Dynamics
    • Percent Revenue Forecast by Product Type

    Antibody Therapies Segment Analysis

    • Antibody Therapies-Overview of Top 10 Products
    • Market Engineering Measurements
    • Revenue Forecast
    • Revenue Forecast Discussion
    • Anticipated Key Product Launches
    • Changing Dynamics
    • Technology Trends in the Antibody Therapy Platform

    Recombinant Proteins Segment Analysis

    • Recombinant Proteins-Overview of Top 10 Products
    • Market Engineering Measurements
    • Revenue Forecast
    • Revenue Forecast Discussion
    • Anticipated Key Product Launches
    • Changing Dynamics

    Vaccines Segment Analysis

    • Vaccines-Overview of Top 10 Products
    • Market Engineering Measurements
    • Revenue Forecast
    • Revenue Forecast Discussion
    • Anticipated Key Product Launches
    • Changing Dynamics

    Cell & Gene Therapy Segment Analysis

    • Cell & Gene Therapy-Overview of Top 10 Products
    • Market Engineering Measurements
    • Revenue Forecast
    • Revenue Forecast Discussion
    • Technology Trends in the Cell Therapy Platform
    • Anticipated Key Product Launches
    • Changing Dynamics
    • Technology Trends in RNA and Viral Vector Platforms

    Companies to Action-Pipeline Analysis

    • Roche AG
    • AMGEN
    • Sanofi
    • AbbVie
    • Novo Nordisk
    • Merck
    • Pfizer
    • Johnson & Johnson
    • Eli Lilly
    • GlaxoSmithKline

    Growth Opportunities

    • Major Growth Opportunities
    • Growth Opportunity 1-ADCs/Polyclonal Antibodies
    • The Future Trends in Antibody Therapy
    • ADC Pipeline Analysis
    • ADCs-Need for Outsourcing
    • Bio-CDMO Benchmarking-ADC Development and Manufacturing Services
    • Growth Opportunity 2-RNA-based Therapies & Vaccines
    • Strategic Imperatives for Better Vaccines
    • RNA Therapy Pipeline Analysis and Industry Partnerships
    • mRNA Technology set to Revolutionize Vaccine Therapies
    • Growth Opportunity 3-Gene Therapy Advancements
    • Investments & Partnerships Advancing CRISPR/Cas Gene Editing Technology
    • Gene Therapy-Collaborations and Partnerships
    • CDMOs to Drive the Growth of Gene Therapy
    • Growth Opportunity Matrix

    The Last Word-Strategic Considerations for Staying on the Growth Trajectory

    • Top 3 Predictions for the Market
    • Legal Disclaimer

    Appendix

    • Market Engineering Methodology
    • List of Key Companies Included in this Research Service
    • List of Exhibits
    • List of Exhibits (continued)
    • List of Exhibits (continued)
    • List of Exhibits (continued)